Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Peng, Hui Zhou(Hunan Cancer Hospital), Jianmin Yang(Canadian Food Inspection Agency), Xinhua Du, Xiuhua Sun(Dalian Medical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Yongping Song(First Affiliated Hospital of Zhengzhou University), Wei Li(First Hospital of Jilin University), Xiong Wang, Yan Xiong(Peking University), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenqi Jiang(Sun Yat-sen University Cancer Center), Wenbin Qian(Ministry of Education of the People's Republic of China), Ming Hou(Qilu Hospital of Shandong University), Chuan Jin(Guangzhou Medical University Cancer Hospital), Yuhuan Gao(Hebei Medical University), Zhengming Jin(Soochow University), Liqun Zou(Sichuan University), Lugui Qiu(Institute of Hematology & Blood Diseases Hospital), Jianfeng Zhou(Tongji Hospital)
Cited by 41
Related Papers
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256